Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]-Fluoromannitol PET Contrast Agent Kinetics and Safety
NCT07110519Phase 1Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-fluoromannitol, sponsored by St. Jude Children's Research Hospital. Primary endpoints: Safety of [18F]fluoromannitol administration at 4 days and Biodistribution of [18F]fluoromannitol at 3 months. Started Sep 2025; status: active, not recruiting.
02
Drugs
18F-fluoromannitol
Beyond the preview
Go deeper on NCT07110519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110519.